Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now?

<p>Is TEVA a good stock to buy? We came across a <a href="https://ditlev.substack.com/p/tevas-teva-pivot-to-growth-hits-high">bullish thesis </a>on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited's share was trading at $31.52 as of March 10th. TEVA’s trailing and forward P/E were 26.03 and 11.60 respectively according to Yahoo Finance.</p>
<p>Teva Pharmaceutical Industries (TEVA) has entered a new phase of growth as the company continues executing its “Pivot to Growth” strategy, transforming from a traditional generics manufacturer into a higher-margin innovative biopharmaceutical company. Following its Q4 and full-year 2025 results, Teva reported revenues of $17.3 billion, representing 5% year-over-year growth and marking the third consecutive year of revenue expansion.</p>
<p>The company’s growth profile is increasingly driven by its innovative portfolio, highlighted by its three core branded medicines—Austedo, Ajovy, and Uzedy—which together surpassed $1 billion in combined quarterly revenue for the first time in the company’s history. Austedo remains the primary growth engine, generating $2.26 billion in 2025 sales (+34%), supported by strong adoption of its once-daily XR formulation.</p>
<p>Ajovy delivered $673 million in global revenue (+30%), while Uzedy, a rapidly expanding long-acting injectable therapy, grew 63% to $191 million. These innovative medicines now play a central role in Teva’s strategy as the company continues to stabilize its global generics franchise, which generated approximately $9.4 billion in revenue.</p>
<p>Financially, Teva delivered strong results across key metrics in 2025, including adjusted EBITDA of $5.3 billion (+12%), non-GAAP EPS of $2.93 (+19%), and free cash flow of $2.4 billion. The company also made meaningful progress on balance sheet improvement, reducing net debt to $13.3 billion and lowering its net debt-to-EBITDA ratio to 2.5x as it targets 2.0x by 2027. Operational improvements are supported by the Teva Transformation program, which aims to generate $700 million in cost savings by 2027, with roughly 20% already achieved.</p>
<p>Looking ahead, Teva expects 2026 to be a transition year as it absorbs a $1.1 billion headwind from generic Revlimid erosion, guiding revenues to $16.4–$16.8 billion while maintaining strong profitability and free cash flow.</p>
<p>Despite this near-term pressure, the company’s late-stage pipeline—estimated at more than $10 billion in peak sales potential—along with continued expansion of its innovative portfolio positions Teva for sustained mid-single-digit growth through the end of the decade. As leverage declines and free cash flow strengthens, investors increasingly view Teva as a biopharma turnaround with meaningful upside potential as the market begins to recognize the value of its evolving business mix.</p>